Enoblituzumab ELISA Kit

SKU: DV612018

Size:96T

Applications:ELISA

Accession:Q5ZPR3

Stability and Storage:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method:Colorimetric

Sample type:Plasma, Serum

Assay type:Quantitative

Sensitivity:0.156 μg/ml

Range:0.31-5 μg/mL

Recovery:80-120%

Properties:

Experimental Procedure:

Background:Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.

Alternative Names:MG-A271, , 1353485-38-7

Shipping:2-8 ℃

Note:For Research Use Only.